An interventional study of LLS Program in Leukemia, Lymphoma and Myeloma, sponsored by University of Miami. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by University of Miami · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,668 studies in Leukemia with a site in United States — 113 open to participants now, 181 under way, 11 of them phase 3. Leukemia · United States.
Among the 1,668 studies in Leukemia with a site in United States, this one is the 53rd largest by planned enrollment of the 1,350 interventional ones that give a count, is one of 24 that started in 2025, is one of 147 with no phase, reaches primary completion later than 47 of the 178 other live ones, and was the 1,577th registered.
2,382 studies on the registry are indexed under Leukemia; 252 are open to participants now.
Browse Leukemia studies →113 of the 1,668 studies in Leukemia with a site in United States are open now. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 18+
Charm Therapeutics · Sites in United States, United Kingdom
Ages 18+
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–110 · Healthy volunteers
Laguna Biotherapeutics, Inc. · Sites in United States
Ages 18 mo–39 yrs
Massachusetts General Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 206 Leukemia studies recruiting now, 111 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 85 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,668 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 617 · Phase 2 827 · Phase 3 123 · Phase 4 12
First in 1986; this study’s year is marked. 24 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 40 across 1,770 interventional studies indexed under Leukemia.
Median enrollment 35 across the 1,350 interventional studies, 150 across the 153 observational. Of the 1,395 that completed or were terminated, 545 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
313 of 1,668 have an industry lead sponsor. The 10 most frequent:
University of Miami is the lead sponsor of 843 studies on the registry; 166 are open to participants now.
Of its 115 completed or terminated interventional studies of FDA-regulated products, 97 (84%) have results posted.
University of Miami has 3 studies filed under Leukemia — fewer than ten, so there is no comparison to draw.
53 of the studies in Leukemia with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07504458Phase 3Quetzal TherapeuticsPivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia | 2027-03 |
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
| NCT05745285University of MiamiLeukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care | 2026-11-30 |
| NCT06152809Dana-Farber Cancer InstituteCIML NK Cells With Venetoclax for AML | 2026-11-30 |
Add all 53 to your calendar (.ics) → With an account.
Among the 1,668 studies in Leukemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn about the impact that the services and programs provided by Blood Cancer United (formerly, The Leukemia and Lymphoma Society) have among patients with blood cancer, such as access to care, quality of life, and financial burden.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have received, be receiving, or be planning to receive primary or relapse treatment for leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN) and meet at least one of the following criteria:
Exclusion Criteria:
Do not meet at least one of the following criteria if treated or planning to get treated for leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN):
Participants in the LLS Program and Usual Care condition will receive LLS services such as information, services, and financial aid so that patients can have better access to healthcare and better quality of life. Participants will also receive the standard care. Participants will be in this group for 6 months.
Other: LLS Program
Participants will receive the standard care. Participants will be in this group for 6 months.
The intervention will be conducted virtually. Participants will receive LLS's free patient and caregiver services including co-pay assistance, transportation and urgent need assistance, a scholarship program for young adult patients and survivors, one-on-one peer-to-peer support, online chats and support groups facilitated by clinical social workers, and nutrition counseling with a registered dietician for 6 months.
Change in number of care needs as measured by the Access to Care Survey
Change in number of care needs will be assessed via the self-report Access to Care Survey which includes access to primary and specialty care, access to medications specific to cancer care, and access to financial resources specific to cancer care. The survey uses a composite score to assess participants' needs. Scores range from 0 to 21 with lower scores indicating better access to care needs.
Time frame: Baseline, 3 month, 6 month
Change in number of medication access problems as measured by the Access to Care Survey
Change in number of medication use will be assessed via the self-report Access to Care Survey which includes access to medications specific to cancer care. The survey uses a composite score to assess participants' medication use. Scores range from 0 to 6 with lower scores indicating better access to medication.
Time frame: Baseline, 3 month, 6 month
Change in general health-related quality of life (HRQL)
The Functional Assessment of Cancer Therapy-General (FACTG) 5 will be administered to evaluate general domains of HRQL. Quality of life is scored on a scale with scores ranging from 0 to 108, with higher scores indicating better health-related quality of life outcomes.
Time frame: Baseline, 3 month, 6 month
Change in treatment satisfaction as measured by FACIT
The 8-item Functional Assessment of Chronic Illness Therapy (FACIT) Treatment Satisfaction - General (TS-G) is a Likert scale designed to assess satisfaction with general medical treatments. A summary score yields a treatment satisfaction composite with higher scores indicating greater treatment satisfaction.
Time frame: Baseline, 3 month, 6 month
Change in financial toxicity as measured by FACIT-COST
The 12-item Functional Assessment of Chronic Illness Therapy - Comprehensive Score for Financial Toxicity (FACIT-COST) is a patient reported outcome measure that describes the financial distress experienced by cancer patients. Score range 0-44 with higher scores indicating better Financial Well-Being.
Time frame: Baseline, 3 month, 6 month
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Nov 2026, 21 months after the start.
Of 103 non-industry interventional studies with no phase under Leukemia, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 128. This study's planned 21 months is below that.
Counting every sponsor, half of 110 studies reached it within 38 months; a quarter within 22 and three quarters within 75.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Oct 2026 → Nov 2026 and completion Nov 2026 → Jul 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.